Endpoint Clinical delivers IRT/RTSM software for patient randomization and trial supply management. See what it offers, pricing model, and who it serves.
Endpoint Clinical, founded in 2009, is a life sciences technology and services provider specializing in Interactive Response Technology (IRT), also known in the industry as Randomization and Trial Supply Management (RTSM). These systems handle two critical, tightly regulated functions in clinical trials: randomly and fairly assigning patients to treatment arms, and managing the logistics of getting the right investigational drug supply to the right site at the right time.
Headquartered in the Boston, Massachusetts area with additional offices across the US, Europe, and Asia, the company has supported over 2,000 clinical studies and more than 1 million patients across 90+ countries. It is now owned by private equity firm Arsenal Capital Partners and competes with other specialized IRT/RTSM vendors such as Suvoda, Cenduit, and YPrime.
Endpoint Clinical's primary platform, PULSE, is built with configurable, pre-validated components so sponsors can support diverse study designs — from simple two-arm trials to complex adaptive designs — without lengthy custom builds, while still meeting regulatory validation requirements. Its newer platform, Elosity, is described as a multi-tenant, AI-assisted system built for faster study start-up and greater elasticity as trial designs change mid-study.
Beyond core randomization and supply management, the company offers 24/7 expert support with defined service level agreements, biostatistical consulting, independent user acceptance testing, and specialized experience across more than 20 therapeutic areas, including oncology and rare disease trials where trial designs are often especially complex.
Endpoint Clinical does not publish pricing. As with most enterprise clinical trial technology vendors, contracts are negotiated per study or per sponsor relationship, typically scoped around trial complexity, number of sites and countries, patient volume, and the level of biostatistical or consulting support required.
Prospective customers — pharmaceutical sponsors, biotechs, and CROs — need to engage directly with Endpoint Clinical's sales and solutions teams to receive a quote, and implementations typically involve a formal validation and onboarding process given the regulated nature of clinical trial software.
It provides Interactive Response Technology (IRT/RTSM) that randomizes patients into trial arms and manages the logistics of getting investigational drug supply to trial sites.
Pricing isn't published; it's negotiated per study or sponsor relationship based on trial complexity, site count, and support needs.
Pharmaceutical and biotech sponsors and the CROs that run clinical trials on their behalf, including several of the world's largest biopharma companies.
PULSE is Endpoint Clinical's established, pre-validated IRT platform, while Elosity is its newer, multi-tenant, AI-assisted platform designed for faster study start-up.
Endpoint Clinical is owned by private equity firm Arsenal Capital Partners and operates as a specialized life sciences technology and services provider.